Related references
Note: Only part of the references are listed.BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
Thomas E. C. Cummin et al.
BLOOD ADVANCES (2020)
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM
Florian Huemer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Fernando Vieira Pericole et al.
FRONTIERS IN ONCOLOGY (2019)
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus et al.
BLOOD CANCER JOURNAL (2019)
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Daniel J. Coleman et al.
SCIENTIFIC REPORTS (2019)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
Emily J. Faivre et al.
MOLECULAR CANCER RESEARCH (2017)
Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)
Thorsten Braun et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations
Mark C. Markowski et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
Lloyd T. Lam et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
Takao Fujisawa et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Do cytogenetics affect the post-remission strategy for older patients with AML in CR1?
James M. Foran
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
Sameem M. Abedin et al.
ONCOTARGETS AND THERAPY (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
Acute Myeloid Leukemia: A Concise Review
Jennifer N. Saultz et al.
JOURNAL OF CLINICAL MEDICINE (2016)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
Anna C. Belkina et al.
JOURNAL OF IMMUNOLOGY (2013)
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Christopher J. Ott et al.
BLOOD (2012)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis
A Dey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
